GIBF

Silexion Therapeutics is a biotechnology company dedicated to developing treatments for KRAS-driven cancers, with a particular emphasis on pancreatic cancer. The company's lead product, SIL-204, is a small interfering RNA (siRNA) therapy delivered in an extended-release formulation aimed at treating locally advanced pancreatic cancer. Silexion is actively working on enhancing its product offerings and is planning further clinical trials to improve treatment outcomes for patients with specific KRAS mutations. Through its innovative approach and focus on clinical efficacy, Silexion aims to address significant unmet medical needs in oncology.

BioVersys AG is a biopharmaceutical company based in Basel that specializes in the research and development of innovative drugs aimed at overcoming drug resistance in bacterial pathogens. The company is dedicated to addressing the pressing global health challenge of multidrug-resistant bacterial infections by restoring the effectiveness of existing antibiotics. BioVersys utilizes its proprietary TRIC (Transcriptional Regulator Inhibitory Compounds) technology platform to discover new therapies that inhibit bacterial resistance mechanisms. This approach not only targets novel bacterial pathways but also provides healthcare professionals with new treatment options for patients suffering from life-threatening infections caused by resistant bacterial strains.

Nectin Therapeutics Ltd., founded in 2017 and based in Jerusalem, Israel, specializes in the development of monoclonal antibodies targeting members of the Nectin family of receptors and ligands. These antibodies are designed to address immune checkpoint mechanisms that play a crucial role in cancer immunotherapy. By focusing on both solid and hematological malignancies, Nectin Therapeutics aims to create therapies that can overcome the inhibitory pathways utilized by tumors, thereby enhancing the ability of immune cells to eradicate cancer cells. The company's innovative approach seeks to improve patient outcomes in cancer treatment.

Kamari Pharma develops innovative treatments for unmet needs and rare diseases in dermatology.

CoreBone is a developer of a bioactive bone graft material intended for dental, orthopedic, and spine applications. The company specializes in a patented technology that incorporates bioactive minerals, such as silicium, into the structure of corals during their growth. This innovative approach results in a 100% mineral bone graft material that exhibits bone-like qualities, including strength, porosity, resorption, and bioactivity, while eliminating the risks associated with human or animal-derived materials. Founded by CEO Ohad Schwartz and CTO Prof. Itzhak Binederman, CoreBone has established a strong intellectual property portfolio and possesses significant expertise in cultivating coral for medical use, positioning itself as a leader in the development of natural alternatives for bone grafting.

Alpha Omega is a global company, offering a plethora of pioneering products, along with consistent innovation and uncompromising quality and service. Alpha Omega is committed to Improving the quality of patient care in the areas of neurology and neurosurgery by developing superior technological solutions.